We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

63 hedge funds and large institutions have $406M invested in Dianthus Therapeutics in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 7

225% more capital invested

Capital invested by funds: $125M → $406M (+$281M)

129% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 7

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

17% more funds holding

Funds holding: 54 → 63 (+9)

0.47% more ownership

Funds ownership: 4.15% → 4.62% (+0.47%)

Holders
63
Holders Change
+9
Holders Change %
+16.67%
% of All Funds
1.36%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
16
Increased
23
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
+$19.7M
2
BlackRock
BlackRock
New York
+$6.24M
3
EAM
Eventide Asset Management
Massachusetts
+$4.52M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.94M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.65M

Top Sellers

Rank Fund Capital Flow
1
Fidelity International
Fidelity International
Bermuda
-$3.59M
2
LCM
Laurion Capital Management
New York
-$1.85M
3
EC
EcoR1 Capital
California
-$1.1M
4
ACA
Anchor Capital Advisors
Massachusetts
-$1.03M
5
HMC
Harvard Management Company
Massachusetts
-$849K
Name Holding Trade Value Shares
Change 		Change in
Stake
EP
51
Elkfork Partners
Oregon
$28K – – –
MSA
52
Marino Stram & Associates
Massachusetts
$27K – – –
PMAM
53
Penn Mutual Asset Management
Pennsylvania
$26K +$279K +1,619 New
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$21K +$14K +81 New
TAM
55
Tyers Asset Management
Texas
$20K – – –
AIP
56
Ameritas Investment Partners
Nebraska
$20K +$9.14K +53 +252%
SO
57
STRS Ohio
Ohio
$19K – – –
CHP
58
Cable Hill Partners
Oregon
$16K – – –
TRCT
59
Tower Research Capital (TRC)
New York
$13K +$6.38K +37 +285%
VFA
60
Valeo Financial Advisors
Indiana
$8K – – –
SWM
61
SeaCrest Wealth Management
New York
$7K – – –
Daiwa Securities Group
62
Daiwa Securities Group
Japan
$4K +$2.42K +14 New
MAM
63
Meeder Asset Management
Ohio
$1K +$1.03K +6 New
Fidelity International
64
Fidelity International
Bermuda
– -$3.59M -39,350 Closed
ACA
65
Anchor Capital Advisors
Massachusetts
– -$1.03M -11,344 Closed
SM
66
Sabby Management
Florida
– -$611K -6,697 Closed
OAM
67
Oxford Asset Management
United Kingdom
– -$128K -1,403 Closed
Two Sigma Investments
68
Two Sigma Investments
New York
– -$104K -1,145 Closed
MOS
69
MGO One Seven
Ohio
– -$1K -19 Closed
1 2
3

DNTH Hedge Fund Activity: Q1 2019 in Review

63 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2019, worth a combined $406M — up 225% from $125M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new DNTH positions and 7 closed out — a net gain of 9 holders — while 23 added to existing stakes and 7 trimmed.

The largest buyer was Gilder Gagnon Howe & Co, opening a new position worth an estimated $19.7M. The largest seller was Fidelity International, exiting entirely with an estimated $3.59M sold.

  • 63 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2019, up from 54 in Q4 2018.
  • Funds reported $406M of Dianthus Therapeutics stock for Q1 2019, up 225% quarter-over-quarter.
  • 16 funds opened new Dianthus Therapeutics positions in Q1 2019 and 7 closed out, a net change of +9 holders.
  • The largest Dianthus Therapeutics buyer in Q1 2019 was Gilder Gagnon Howe & Co, an estimated $19.7M added.
  • The largest Dianthus Therapeutics seller in Q1 2019 was Fidelity International, an estimated $3.59M sold.

Based on aggregated 13F filings for Q1 2019.